NASDAQ:ENTA Enanta Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $45.01 -0.66 (-1.45%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$43.00▼$46.5750-Day Range$38.13▼$75.7952-Week Range$37.59▼$102.00Volume345,595 shsAverage Volume249,054 shsMarket Capitalization$932.29 millionP/E RatioN/ADividend YieldN/APrice Target$74.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock Forecast (MarketRank)Overall MarketRank™2.26 out of 5 starsMedical Sector315th out of 1,418 stocksPharmaceutical Preparations Industry132nd out of 679 stocksAnalyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.14, Enanta Pharmaceuticals has a forecasted upside of 64.6% from its current price of $45.05.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Community Rank Outperform VotesEnanta Pharmaceuticals has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEnanta Pharmaceuticals has received 198 “underperform” votes. (Add your “underperform” vote.)Community SentimentEnanta Pharmaceuticals has received 60.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,967,739.00 in company stock.Percentage Held by Insiders11.74% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.87% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($5.56) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock News HeadlinesJune 24, 2022 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?June 24, 2022 | americanbankingnews.comJMP Securities Reiterates "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)June 23, 2022 | finance.yahoo.comCases climb in Southeast Asia and Europe in latest week as BA.4 and BA.5 subvariants take holdJune 23, 2022 | finance.yahoo.comEnanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with PaxlovidJune 22, 2022 | bizjournals.comEnanta Pharmaceuticals sues Pfizer for patent infringement involving PaxlovidJune 22, 2022 | finance.yahoo.comA small biotech says Pfizer infringed on its patent with PaxlovidJune 22, 2022 | finance.yahoo.comEnanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill PaxlovidJune 22, 2022 | seekingalpha.comEnanta files patent infringement lawsuit against Pfizer over PaxlovidJune 21, 2022 | finance.yahoo.comEnanta Pharmaceuticals Files Patent Infringement Suit Against PfizerJune 18, 2022 | americanbankingnews.comAnalysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $74.14June 16, 2022 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Hold at StockNews.comJune 8, 2022 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022June 1, 2022 | markets.businessinsider.comExpert Ratings for Enanta PharmaceuticalsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees155Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/24/2022Next Earnings (Estimated)8/04/2022Fiscal Year End9/30/2022Price Target and Rating Average Stock Price Forecast$74.14 High Stock Price Forecast$103.00 Low Stock Price Forecast$44.00 Forecasted Upside/Downside+64.7%Consensus RatingModerate Buy Rating Score (0-4)2.71428571428571 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79 million Net Margins-122.68% Pretax Margin-142.57% Return on Equity-28.80% Return on Assets-25.87% Debt Debt-to-Equity RatioN/A Current Ratio11.12 Quick Ratio11.12 Sales & Book Value Annual Sales$97.07 million Price / Sales9.60 Cash FlowN/A Price / Cash FlowN/A Book Value$19.76 per share Price / Book2.28Miscellaneous Outstanding Shares20,713,000Free Float18,281,000Market Cap$932.29 million OptionableOptionable Beta0.67 Enanta Pharmaceuticals Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Enanta Pharmaceuticals stock. View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2022? 7 equities research analysts have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their ENTA stock forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $74.14 in the next twelve months. This suggests a possible upside of 64.7% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Enanta Pharmaceuticals' stock performed in 2022? Enanta Pharmaceuticals' stock was trading at $74.78 on January 1st, 2022. Since then, ENTA stock has decreased by 39.8% and is now trading at $45.01. View the best growth stocks for 2022 here. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Enanta Pharmaceuticals. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.20. The biotechnology company had revenue of $18.72 million for the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the company posted ($1.09) EPS. View Enanta Pharmaceuticals' earnings history. Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the following people: Dr. Jay R. Luly, Pres, CEO & Director (Age 66, Pay $1.23M)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 67, Pay $652.39k)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 70, Pay $729.75k)Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 44, Pay $496.85k)Mr. Brendan Luu, Sr. VP of Bus. Devel.Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. CommunicationsMr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 68)Dr. Nathalie Adda M.D., Consultant (Age 56) (LinkedIn Profile) What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX) and Insmed (INSM). View all of ENTA's competitors. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.13%), Vanguard Group Inc. (7.67%), Farallon Capital Management LLC (7.48%), State Street Corp (6.32%), RA Capital Management L.P. (4.66%) and Northern Trust Corp (4.48%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett. View institutional ownership trends for Enanta Pharmaceuticals. Which institutional investors are selling Enanta Pharmaceuticals stock? ENTA stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Granahan Investment Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Acadian Asset Management LLC, Candriam Luxembourg S.C.A., Vanguard Group Inc., and Citigroup Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last two years include Bruce L A Carter, Jay R Luly, Nathalie Adda, and Paul J Mellett. View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks. Which institutional investors are buying Enanta Pharmaceuticals stock? ENTA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Deep Track Capital LP, State Street Corp, Fairmount Funds Management LLC, Invesco Ltd., BlackRock Inc., Walleye Capital LLC, and Walleye Capital LLC. View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $45.01. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $932.29 million and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? Enanta Pharmaceuticals employs 155 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for Enanta Pharmaceuticals is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here